- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: Navamepent (RX-10045) is a stable resolvin E1 analogue, that is being investigated for clinical efficacy in occular inflammation . Chemically this is an isopropyl ester prodrug of resolvin E1 (an agonist of the chemerin receptor). The chemical structure is claimed in patent US20140275247A1 (as Example 1001) . Findings from animal studies are reported in  and .
|A metabolically stable resolvin E1 analogue, that has completed Phase 2 clinical evaluation in several occular inflammation conditions.|
||Phase 2 clinical trial NCT01639846 has been completed.|
||Phase 2 clinical trials NCT00799552 and NCT01675570 are completed.|